Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Free Cash Flow: 2013-2025

Historic Free Cash Flow for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$46.3 million.

  • Coherus Oncology's Free Cash Flow rose 25.28% to -$46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $388.5 million, marking a year-over-year increase of 134.31%. This contributed to the annual value of -$20.4 million for FY2024, which is 88.33% up from last year.
  • As of Q3 2025, Coherus Oncology's Free Cash Flow stood at -$46.3 million, which was down 110.61% from $436.8 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Free Cash Flow ranged from a high of $436.8 million in Q2 2025 and a low of -$100.0 million during Q4 2022.
  • For the 3-year period, Coherus Oncology's Free Cash Flow averaged around $35.6 million, with its median value being -$30.5 million (2025).
  • In the last 5 years, Coherus Oncology's Free Cash Flow tumbled by 8,343.95% in 2022 and then spiked by 355.63% in 2024.
  • Quarterly analysis of 5 years shows Coherus Oncology's Free Cash Flow stood at -$52.8 million in 2021, then crashed by 89.51% to -$100.0 million in 2022, then spiked by 87.03% to -$13.0 million in 2023, then surged by 320.55% to $28.6 million in 2024, then increased by 25.28% to -$46.3 million in 2025.
  • Its Free Cash Flow was -$46.3 million in Q3 2025, compared to $436.8 million in Q2 2025 and -$30.5 million in Q1 2025.